Navigation Links
Genta Incorporated to Present at the BIO CEO & Investor Conference
Date:2/5/2008

business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to regain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
(Date:12/19/2014)... Fayetteville, Arkansas (PRWEB) December 18, 2014 ... plans to locate its pilot production facility and ... further develop and produce innovative new materials that ... was chosen not only because of its historic, ... regional leaders’ efforts to attract leading edge, technology-based ...
(Date:12/19/2014)... December 18, 2014 Reports from ... United States suffer from one or more chronic health ... cancer. Medication can address some of these diseases, but ... that many sufferers face. While implanted nerve stimulation devices ... the whole nerve, which can induce side effects. ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... MISSISSAUGA, ON, Jan. 6 /PRNewswire-FirstCall/ - Vasogen Inc. ... update on corporate activities. Pursuant to a previously ... alternatives for the purpose of enhancing shareholder value. ... potential opportunities including the sale of the Company, ...
... 6 Accumetrics, Inc. has appointed Andrew Chisholm to ... brings the right mix of energy and expertise to ... next level in terms of our market penetration," says ... knowledge of the medical diagnostics industry and his relationships ...
... Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing ... it has received notification from The NASDAQ Stock Market ... listing on the NASDAQ Global Market. The Company,s common ... at market open under the symbol "BSTC" and will ...
Cached Biology Technology:Vasogen Provides Corporate Update 2Vasogen Provides Corporate Update 3Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics 2BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market 2
(Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... --  News Highlights: , ... Partners Data Lake, an agile data and analytics ... allow researcher and clinicians to explore and develop ... of patients , The Partners Data Lake ... Partners system, breaking down physical barriers for collaboration ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... as career killers, Achilles tendon injuries are among the most ... in post WWII tests, scientists have learned why: Like our ... is a tissue that does not repair itself. This discovery ... . "Tendon injury is a very common disease, which ...
... academic journal publisher, founded on the principles of affordability, innovation, ... launched by Jason Hoyt (formerly at Mendeley and Stanford University) ... been shaped from the premise that ,if society can set ... then why shouldn,t academics be given the opportunity to openly ...
... University researchers "cured" a strain of bacteria of its ... has implications for a long-standing public health crisis. ... managed to remove the ability of the Pseudomonas aeruginosa ... its access to food and oxygen. Over ...
Cached Biology News:Fallout from nuclear testing shows that the Achilles tendon can't heal itself 2PeerJ publishes its first articles 2Lack of energy an enemy to antibiotic-resistant microbes 2Lack of energy an enemy to antibiotic-resistant microbes 3
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: